Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
about
Recent advances in understanding proton coupled peptide transport via the POT familyDevelopment of a peptide-drug conjugate for prostate cancer therapy.Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis.Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation.Prodrug approach to improve absorption of prednisoloneSmall endogenous molecules as moiety to improve targeting of CNS drugs.FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivoTransport of drugs by proton-coupled peptide transporters: pearls and pitfalls.Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery.Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles.Transporter effects on cell permeability in drug delivery.Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its Application in Pharmacokinetic StudiesAmino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, LopinavirOcular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir.Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea.Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug.Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir.Molecular engineering solutions for therapeutic peptide delivery.Amino Acids in the Development of Prodrugs
P2860
Q28073606-5B86CD6D-3F8C-4E72-A4C8-AC744A4CDA17Q35184864-B0F52C42-5E69-49B0-85E9-33BC63BB7FDAQ35892584-7EC4C888-BBDB-41E5-875F-253DE2C57212Q35892589-51F3311E-0CD7-4D7C-A873-6E0D58C81906Q35950189-E058A186-0CAD-4B10-B052-C49348E5BC92Q36065879-4370D48D-CF87-4BF4-9164-C9CF47DE3B12Q37083640-52640E13-720F-4310-9D0C-48DEA778EAECQ37515414-D3DB89D9-1B0B-45A9-BD0A-9A053EACCF0EQ37824864-E43226BB-B4B2-4EFE-B578-4273FAAC212BQ38050686-0B1BFEE4-9212-4B80-8BF1-16B1FD350A71Q38764703-0123E3B2-F31F-4011-9FFB-BA3EF746055EQ38905979-FADCC07C-F586-48EC-8341-21CE48FF0839Q39281577-20C79651-4D47-4BE9-81BF-6EE4BB448B02Q39395865-3C09950C-6B70-4ACE-8127-C2770AACF67FQ39557119-4CF4D2F3-BF1C-4BEF-9A0B-0F4224FAB34BQ39760193-045DA1A6-D829-4127-B1E0-4C7403176151Q40569235-BAF4AA42-7FD1-4B5C-ABC9-97CC1B3E5060Q43168123-B52A3160-981C-4EE0-B694-1046730C8BDAQ45722674-DFA67469-88B0-41CF-958A-3505F8030543Q47680427-019ECF55-06EA-46B3-9FF4-25D26ACC4DA7Q58696356-CD935DD6-C01C-470D-9C3D-1B9983875FDF
P2860
Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
@en
Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
@nl
type
label
Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
@en
Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
@nl
prefLabel
Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
@en
Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
@nl
P2093
P2860
P1476
Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.
@en
P2093
Ashim K Mitra
Dhananjay Pal
Ritesh Jain
S H S Boddu
Sheetal Agarwal
Swapan Samanta
P2860
P356
10.1016/J.IJPHARM.2008.03.031
P407
P577
2008-03-28T00:00:00Z